Item request has been placed!

Item request cannot be made.

Processing Request

نتائج البحث

Display Settings

النتائج لكل صفحة: 10

Sort By: Relevance

Filter

فلترة النتائج

إعادة تعيين خيارات الفبترة

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.

Authors : Ludwig, Heinz¹ (AUTHOR) ; Pönisch, Wolfram² (AUTHOR); Knop, Stefan³ (AUTHOR)

Source: Leukemia & Lymphoma. Feb2020, Vol. 61 Issue 2, p377-386. 10p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial.

Authors : Schjesvold, Fredrik^1,2 (AUTHOR) ; Goldschmidt, Hartmut³ (AUTHOR); Maisnar, Vladimir⁴ (AUTHOR)

Source: European Journal of Haematology. May2020, Vol. 104 Issue 5, p443-458. 16p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

伊沙佐米对人胃癌细胞株SGC -7901生物学行为的影响及其机制.

Authors : 姜灵¹ ; 戴社教¹; 陈芬荣¹

Source: Shandong Medical Journal. 8/15/2020, Vol. 60 Issue 23, p34-37. 4p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation.

Authors : Dash, Ajeeta B.¹ (AUTHOR) ; Zhang, Jacob¹ (AUTHOR); Shen, Lei¹ (AUTHOR)

Source: European Journal of Haematology. Sep2020, Vol. 105 Issue 3, p274-285. 12p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma.

Authors : Di Bacco, Alessandra¹ (AUTHOR) ; Bahlis, Nizar J.² (AUTHOR); Munshi, Nikhil C.³ (AUTHOR)

Source: European Journal of Haematology. Jul2020, Vol. 105 Issue 1, p35-46. 12p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia.

Authors : Sánchez, Gina^1,2 (AUTHOR) ; Chalmers, Stefanie¹ (AUTHOR); Ahumada, Xavier¹ (AUTHOR)

Source: PLoS ONE. 5/26/2020, Vol. 15 Issue 5, p1-13. 13p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice.

Authors : Harris, Michael A.¹ (AUTHOR) ; Miles, Mark A.¹ (AUTHOR) ; Shekhar, Tanmay M.¹ (AUTHOR)

Source: Cancers. May2020, Vol. 12 Issue 5, p1207. 1p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.

Authors : Hinsley, Samantha¹ (AUTHOR); Walker, Katrina¹ (AUTHOR) ; Sherratt, Debbie¹ (AUTHOR)

Source: Trials. 10/2/2020, Vol. 21 Issue 1, p1-11. 11p. 1 Illustration, 1 Diagram, 4 Charts.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A phase 0 analysis of ixazomib in patients with glioblastoma.

Authors : Quillin, Joseph¹ (AUTHOR) ; Patel, Rikesh² (AUTHOR); Herzberg, Eric³ (AUTHOR)

Source: Molecular & Clinical Oncology. Nov2020, Vol. 13 Issue 5, pN.PAG-N.PAG. 1p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Ixazomib Improves Bone Remodeling and Counteracts Sonic Hedgehog Signaling Inhibition Mediated by Myeloma Cells.

Authors : Tibullo, Daniele¹ (AUTHOR) ; Longo, Anna¹ (AUTHOR) ; Vicario, Nunzio² (AUTHOR)

Source: Cancers. Feb2020, Vol. 12 Issue 2, p323. 1p.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.

Quality of life is maintained with ixazomib maintenance in post‐transplant newly diagnosed multiple myeloma: The TOURMALINE‐MM3 trial.

伊沙佐米对人胃癌细胞株SGC -7901生物学行为的影响及其机制.

Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation.

c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma.

Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia.

The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice.

The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.

A phase 0 analysis of ixazomib in patients with glioblastoma.

Ixazomib Improves Bone Remodeling and Counteracts Sonic Hedgehog Signaling Inhibition Mediated by Myeloma Cells.

اتصل بنا

اتبع